Kameel Farag Increases Stake in AKTX
Interim CFO Kameel Farag buys 18,830 shares of AKTX, spending over $105,000.
Key Points
- Kameel Farag, the Interim CFO of AKTX, purchased 18,830 shares on June 24, 2026, at an average price of $5.58 per share, totaling $105,005.50.
- Shares of AKTX traded at $10.76 on Friday, reflecting recent insider activity.
- HC Wainwright & Co. maintained a buy rating for AKTX with a $27.00 price target as of April 2, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kameel Farag, the Interim CFO of AKTX, has made a notable move by purchasing 18,830 shares of the company. This transaction took place on June 24, 2026, at an average price of $5.58 per share, amounting to a total investment of $105,005.50. This was not part of a pre-planned trading arrangement.
Insider Buying and Selling at Akari Therapeutics, Plc
On the same day, AKTX's CEO, Gaslightwala Abizer, also bought 21,063 shares. Meanwhile, James Neal made multiple purchases back in December 2025, acquiring shares at prices around $0.40. These insider activities highlight some confidence in the company's prospects.
Other Institutional Activity in AKTX
Institutional investors have shown varied interest in AKTX. Armistice Capital, LLC completely exited its position, reducing its holdings by 2,722,993 shares to zero. Similarly, Cresset Asset Management, LLC also nearly eliminated its stake, selling 821,954 shares. On a different note, IFP Advisors, Inc opened a new position with 186 shares.
Akari Therapeutics, Plc Stock Up 0.5%
Shares of AKTX traded at $10.76 on Friday. The stock's recent activity reflects insider transactions and institutional movements. Investors are keeping an eye on these changes as they assess the company's direction.
$AKTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
HC Wainwright & Co. maintained its buy rating on AKTX with a price target of $27.00 as of April 2, 2026. Ladenburg Thalmann initiated coverage with a buy rating and a $1.00 target earlier this year. The consensus among analysts suggests a positive outlook for the stock.
About AKTX
AKTX is involved in developing innovative therapies and treatments, focusing on addressing unmet medical needs. The company is engaged in research and development, aiming to bring new solutions to the healthcare industry.
Bottom Line
Kameel Farag's recent share purchase in AKTX signals insider confidence in the company's future. While institutional investors have shown mixed reactions, analysts maintain a positive outlook. As always, these insights are based on past filings and do not necessarily reflect current positions.
Get Akari Therapeutics, Plc alerts
New 13F filings, insider trades, and analyst moves on $AKTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.